Metabolism · Phase 2-3 · pulled 2026-11-06

Type 2 diabetes: trial sites and investigators

25 sites and 10 investigators from 300 completed and terminated Phase 2-3 trials of type 2 diabetes (last 12 years), plus 256 trials recruiting now.

A cited data summary, not a recommendation to select or exclude any site. Every line links to the registry record behind it.

Sites

Sites are listed in the registry's own order: comparable trials listed (most first), ties by latest completion, then name. The Sitecite score is a second column. “Competing now” counts recruiting, active and not-yet-recruiting trials in the same indication at that site.

Type 2 diabetes: sites in the registry's trial-count order, with the Sitecite score as a second column
#	Site	Comparable trials listed	Trials (ClinicalTrials.gov)	Latest completion	Competing now	Score (0-100)
1	Beijing Pinggu Hospital Beijing, China · 24 spellings merged	35 35 completed, 0 terminated	NCT06589765 NCT06672172 NCT06066528 6 trials with titles NCT06589765 A Study of HRS-7535 Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequately Controlled With Metformin completed 2026-05-29 NCT06672172 A Study of HRS-7535 Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequately Controlled With Diet and Exercise completed 2026-04-17 NCT06066528 A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight completed 2026-04-01 NCT06066515 A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight completed 2026-02-20 NCT06065540 A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor completed 2026-01-06 NCT06649773 The Experiment of Noiiglutide Injection in Type 2 Diabetes Patients completed 2025-12-11	2026-05-29	8 NCT07282600 NCT07881432 NCT07351045 NCT07351058	100
2	Jinan Central Hospital Jinan, China · 5 spellings merged	34 34 completed, 0 terminated	NCT06065540 NCT06323174 NCT06323161 6 trials with titles NCT06065540 A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor completed 2026-01-06 NCT06323174 A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise completed 2025-12-22 NCT06323161 A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin completed 2025-10-23 NCT06192108 A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin completed 2025-09-26 NCT06109311 A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor completed 2025-09-15 NCT06045221 A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin completed 2025-08-22	2026-01-06	13 NCT07670416 NCT07282600 NCT07881458 NCT07392190	96
3	Consano Clinical Research, LLC Shavano Park, United States · 2 spellings merged	32 31 completed, 1 terminated	NCT06628362 NCT06926842 NCT06221969 6 trials with titles NCT06628362 A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus completed 2026-10-02 NCT06926842 Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2) completed 2026-08-13 NCT06221969 A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor completed 2026-04-06 NCT06066528 A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight completed 2026-04-01 NCT05803421 A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk completed 2026-03-16 NCT06354660 Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1) completed 2026-02-20	2026-10-02	18 NCT07668336 NCT06897475 NCT07392190 NCT07881432	91
4	Peking University People's Hospital Beijing, China · 7 spellings merged	32 32 completed, 0 terminated	NCT06066528 NCT06066515 NCT06184568 6 trials with titles NCT06066528 A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight completed 2026-04-01 NCT06066515 A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight completed 2026-02-20 NCT06184568 A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity completed 2026-02-09 NCT06235086 A Study of TG103 Injection Combined With Metformin in Treatment of Type 2 Diabetes Mellitus completed 2026-02-03 NCT06258148 A Study of TG103 Injection Monotherapy in Treatment of Type 2 Diabetes Mellitus completed 2026-01-23 NCT06881264 A Study Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes completed 2025-09-19	2026-04-01	25 NCT07923357 NCT07670416 NCT07920640 NCT07282600	100
5	The Second Affiliated Hospital of Nanjing Medical University Nanjing, China · 3 spellings merged	32 32 completed, 0 terminated	NCT06066528 NCT06066515 NCT06065540 6 trials with titles NCT06066528 A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight completed 2026-04-01 NCT06066515 A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight completed 2026-02-20 NCT06065540 A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor completed 2026-01-06 NCT06323174 A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise completed 2025-12-22 NCT06323161 A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin completed 2025-10-23 NCT06192108 A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin completed 2025-09-26	2026-04-01	12 NCT07282600 NCT07881458 NCT07392190 NCT07881432	95
6	Affiliated Hospital of Jiangsu University Zhenjiang, China · 4 spellings merged	28 28 completed, 0 terminated	NCT06066528 NCT06066515 NCT06065540 6 trials with titles NCT06066528 A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight completed 2026-04-01 NCT06066515 A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight completed 2026-02-20 NCT06065540 A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor completed 2026-01-06 NCT06323174 A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise completed 2025-12-22 NCT06323161 A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin completed 2025-10-23 NCT06192108 A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin completed 2025-09-26	2026-04-01	4 NCT07064473 NCT07351045 NCT07351058 NCT07797335	95
7	Palm Research Center Inc-Vegas Las Vegas, United States · 8 spellings merged	26 26 completed, 0 terminated	NCT06926842 NCT05929066 NCT05803421 6 trials with titles NCT06926842 Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2) completed 2026-08-13 NCT05929066 A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight completed 2026-04-30 NCT05803421 A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk completed 2026-03-16 NCT06323161 A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin completed 2025-10-23 NCT05936151 A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes completed 2025-10-21 NCT06326047 A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes completed 2025-10-13	2026-08-13	12 NCT07881432 NCT07783802 NCT07754461 NCT07064473	87
8	Diablo Clinical Research, Inc. Walnut Creek, United States · 4 spellings merged	25 23 completed, 2 terminated	NCT06603571 NCT06926842 NCT05929079 6 trials with titles NCT06603571 A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes completed 2026-09-14 NCT06926842 Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2) completed 2026-08-13 NCT05929079 A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight completed 2026-06-16 NCT06221969 A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor completed 2026-04-06 NCT06066528 A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight completed 2026-04-01 NCT05803421 A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk completed 2026-03-16	2026-09-14	11 NCT07533175 NCT07595549 NCT07282600 NCT07890376	88
9	PharmQuest Life Sciences LLC Greensboro, United States · 4 spellings merged	24 24 completed, 0 terminated	NCT06926842 NCT06221969 NCT05803421 6 trials with titles NCT06926842 Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2) completed 2026-08-13 NCT06221969 A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor completed 2026-04-06 NCT05803421 A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk completed 2026-03-16 NCT06065540 A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor completed 2026-01-06 NCT06326047 A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes completed 2025-10-13 NCT06045221 A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin completed 2025-08-22	2026-08-13	7 NCT07282600 NCT07754461 NCT07668388 NCT07817251	91
10	Accellacare Wilmington, United States · 8 spellings merged	23 23 completed, 0 terminated	NCT06628362 NCT06221969 NCT06066528 6 trials with titles NCT06628362 A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus completed 2026-10-02 NCT06221969 A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor completed 2026-04-06 NCT06066528 A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight completed 2026-04-01 NCT05803421 A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk completed 2026-03-16 NCT06354660 Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1) completed 2026-02-20 NCT06066515 A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight completed 2026-02-20	2026-10-02	11 NCT07595549 NCT07392190 NCT07064473 NCT06383390	88
11	Velocity Clinical Res-Dallas Dallas, United States	23 23 completed, 0 terminated	NCT06065540 NCT06323174 NCT06542874 6 trials with titles NCT06065540 A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor completed 2026-01-06 NCT06323174 A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise completed 2025-12-22 NCT06542874 A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes completed 2025-10-24 NCT06323161 A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin completed 2025-10-23 NCT06326047 A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes completed 2025-10-13 NCT06269107 A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4) completed 2025-07-08	2026-01-06	2 NCT07220759 NCT03811561	85
12	Juno Research Houston, United States · 11 spellings merged	22 22 completed, 0 terminated	NCT06628362 NCT06926842 NCT05929066 6 trials with titles NCT06628362 A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus completed 2026-10-02 NCT06926842 Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2) completed 2026-08-13 NCT05929066 A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight completed 2026-04-30 NCT06066528 A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight completed 2026-04-01 NCT05803421 A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk completed 2026-03-16 NCT06066515 A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight completed 2026-02-20	2026-10-02	16 NCT07282600 NCT06897475 NCT07881458 NCT07392190	91
13	StudyMetrix Research City of Saint Peters, United States · 3 spellings merged	22 21 completed, 1 terminated	NCT06603571 NCT05929079 NCT05929066 6 trials with titles NCT06603571 A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes completed 2026-09-14 NCT05929079 A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight completed 2026-06-16 NCT05929066 A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight completed 2026-04-30 NCT06221969 A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor completed 2026-04-06 NCT06066528 A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight completed 2026-04-01 NCT05803421 A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk completed 2026-03-16	2026-09-14	3 NCT07890376 NCT06383390 NCT07589608	91
14	Lillestol Research LLC Fargo, United States · 3 spellings merged	22 22 completed, 0 terminated	NCT06797869 NCT06534411 NCT05929079 6 trials with titles NCT06797869 A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy completed 2026-08-05 NCT06534411 A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both completed 2026-07-09 NCT05929079 A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight completed 2026-06-16 NCT05929066 A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight completed 2026-04-30 NCT05803421 A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk completed 2026-03-16 NCT06542874 A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes completed 2025-10-24	2026-08-05	3 NCT07282600 NCT07064473 NCT07564414	91
15	Valley Clinical Trials, Inc. Northridge, United States · 5 spellings merged	22 22 completed, 0 terminated	NCT05536804 NCT05929079 NCT06221969 6 trials with titles NCT05536804 A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes completed 2026-07-30 NCT05929079 A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight completed 2026-06-16 NCT06221969 A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor completed 2026-04-06 NCT05803421 A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk completed 2026-03-16 NCT06323174 A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise completed 2025-12-22 NCT06323161 A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin completed 2025-10-23	2026-07-30	9 NCT07900633 NCT07754461 NCT06383390 NCT07817251	87
16	Valley Research Fresno, United States	21 21 completed, 0 terminated	NCT05929066 NCT05803421 NCT06131372 6 trials with titles NCT05929066 A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight completed 2026-04-30 NCT05803421 A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk completed 2026-03-16 NCT06131372 A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo completed 2025-11-06 NCT06323161 A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin completed 2025-10-23 NCT06326047 A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes completed 2025-10-13 NCT06340854 A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes completed 2025-06-13	2026-04-30	0	87
17	Tianjin Medical University General Hospital Tianjin, China · 8 spellings merged	20 20 completed, 0 terminated	NCT06649344 NCT06066528 NCT06066515 6 trials with titles NCT06649344 A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes completed 2026-07-18 NCT06066528 A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight completed 2026-04-01 NCT06066515 A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight completed 2026-02-20 NCT05872620 A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes completed 2025-08-08 NCT04255433 A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes completed 2025-06-12 NCT06871761 A Trial Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes completed 2025-05-13	2026-07-18	4 NCT07881458 NCT07900633 NCT06778967 NCT07156539	100
18	UT Southwestern Med Cntr Dallas, United States · 5 spellings merged	20 19 completed, 1 terminated	NCT06534411 NCT06326047 NCT04974528 6 trials with titles NCT06534411 A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both completed 2026-07-09 NCT06326047 A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes completed 2025-10-13 NCT04974528 Afrezza® INHALE-1 Study in Pediatrics completed 2025-04-29 NCT05394519 A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight completed 2025-02-03 NCT05649137 A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight completed 2024-12-13 NCT03914326 A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes completed 2024-08-23	2026-07-09	6 NCT07533175 NCT07392190 NCT06383390 NCT03811561	86
19	The Fourth Affiliated Hospital of Harbin Medical University Harbin, China · 2 spellings merged	20 20 completed, 0 terminated	NCT06192108 NCT06045221 NCT05872620 6 trials with titles NCT06192108 A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin completed 2025-09-26 NCT06045221 A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin completed 2025-08-22 NCT05872620 A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes completed 2025-08-08 NCT06350890 Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes completed 2025-08-04 NCT06353347 Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Inadequately Controlled With Metformin completed 2025-07-30 NCT06415773 Effects of Berberine Ursodeoxycholate (HTD1801) Versus Dapagliflozin in Patients With Type 2 Diabetes Inadequately Controlled With Metformin completed 2025-07-25	2025-09-26	3 NCT06993792 NCT06972459 NCT06972472	100
20	Dallas Diabetes Research Center Dallas, United States · 4 spellings merged	20 20 completed, 0 terminated	NCT04255433 NCT05662332 NCT04184622 6 trials with titles NCT04255433 A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes completed 2025-06-12 NCT05662332 A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1) completed 2024-07-19 NCT04184622 A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight completed 2024-07-06 NCT05232071 Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus completed 2024-06-04 NCT05275400 A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin completed 2024-05-15 NCT05362058 A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time completed 2024-04-10	2025-06-12	1 NCT04083339	96
21	Intend Research, LLC Norman, United States · 2 spellings merged	20 20 completed, 0 terminated	NCT05514535 NCT05662332 NCT05275400 6 trials with titles NCT05514535 A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE) completed 2025-04-09 NCT05662332 A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1) completed 2024-07-19 NCT05275400 A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin completed 2024-05-15 NCT05352815 A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec completed 2024-04-23 NCT05362058 A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time completed 2024-04-10 NCT04660643 A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss completed 2023-05-18	2025-04-09	0	93
22	Iowa Diabetes and Endocrinology Research Center West Des Moines, United States · 4 spellings merged	19 17 completed, 2 terminated	NCT06603571 NCT06926842 NCT05803421 6 trials with titles NCT06603571 A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes completed 2026-09-14 NCT06926842 Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2) completed 2026-08-13 NCT05803421 A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk completed 2026-03-16 NCT05872620 A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes completed 2025-08-08 NCT07030868 A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes terminated 2025-07-29 Stop reason on the record: “Study terminated for strategic business reasons” NCT04255433 A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes completed 2025-06-12	2026-09-14	9 NCT07392190 NCT07890376 NCT06383390 NCT07296484	91
23	New Horizon Research Center Miami, United States · 2 spellings merged	19 18 completed, 1 terminated	NCT06603571 NCT06797869 NCT06534411 6 trials with titles NCT06603571 A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes completed 2026-09-14 NCT06797869 A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy completed 2026-08-05 NCT06534411 A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both completed 2026-07-09 NCT05929066 A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight completed 2026-04-30 NCT06221969 A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor completed 2026-04-06 NCT06066528 A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight completed 2026-04-01	2026-09-14	9 NCT07282600 NCT07392190 NCT07890376 NCT07754461	89
24	InnoDiab Forschung GmbH Essen, Germany · 3 spellings merged	19 19 completed, 0 terminated	NCT06066528 NCT06066515 NCT06065540 6 trials with titles NCT06066528 A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight completed 2026-04-01 NCT06066515 A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight completed 2026-02-20 NCT06065540 A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor completed 2026-01-06 NCT06542874 A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes completed 2025-10-24 NCT06192108 A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin completed 2025-09-26 NCT05872620 A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes completed 2025-08-08	2026-04-01	14 NCT07282600 NCT06897475 NCT07881432 NCT07064473	91
25	Institut für Diabetesforschung GmbH Münster - Dr. med. Rose Münster, Germany · 3 spellings merged	19 19 completed, 0 terminated	NCT06066528 NCT06066515 NCT06542874 6 trials with titles NCT06066528 A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight completed 2026-04-01 NCT06066515 A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight completed 2026-02-20 NCT06542874 A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes completed 2025-10-24 NCT06192108 A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin completed 2025-09-26 NCT05872620 A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes completed 2025-08-08 NCT06340854 A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes completed 2025-06-13	2026-04-01	6 NCT07282600 NCT06897475 NCT07881458 NCT07064473	90

Investigators

Principal investigators and study chairs of the comparable trials, most trials first. Papers are matched on name, affiliation and condition; the match confidence is shown on each.

Type 2 diabetes: principal investigators and study chairs of the comparable trials, with matched papers
#	Investigator	Comparable trials	Trials (ClinicalTrials.gov)	Papers (PubMed)
1	Linong Ji Peking University People's Hospital	4	NCT04807348 NCT07057271 NCT07058545 NCT04504396	PMID 42978062 Journal of diabetes, 2026 · High match PMID 42901325 Kidney international, 2026 · High match PMID 42862437 Advances in therapy, 2026 · High match
2	Juan A Becerra Hernández Centro de Investigación y Avances Médicos Especializados (Red OSMO)	3	NCT04841096 NCT04618744 NCT04564846	No paper matched at High or Medium confidence
3	hany moustafa ibraheem alzafer hospital , najran , KSA	2	NCT07820111 NCT06186102	No paper matched at High or Medium confidence
4	Yiming Mu Chinese PLA General Hospital	2	NCT06481085 NCT05566028	PMID 42473266 Diabetes, obesity & metabolism, 2026 · High match PMID 42296968 Med (New York, N.Y.), 2026 · High match PMID 42221502 Frontiers in microbiology, 2026 · Medium match
5	Salvador Pérez Jaime Centro de Investigación Médica Aguascalientes (Red OSMO)	2	NCT04841096 NCT04209075	No paper matched at High or Medium confidence
6	xiaoying Li Shanghai Zhongshan Hospital	2	NCT05816057 NCT05801627	PMID 42991559 Frontiers in endocrinology, 2026 · Medium match
7	Bin Gao Tang-Du Hospital	2	NCT04504396 NCT04504370	No paper matched at High or Medium confidence
8	Huige Shao Changsha Central Hospital	2	NCT04504396 NCT04504370	No paper matched at High or Medium confidence
9	Jianhua Ma The First Affiliated Hospital with Nanjing Medical University	2	NCT04504396 NCT04504370	PMID 42936000 Frontiers in microbiology, 2026 · Medium match PMID 42903117 Frontiers in endocrinology, 2026 · High match PMID 42874901 Environmental research, 2026 · High match
10	Jing Yang The First Affiliated Hospital of Shanxi Medical University	2	NCT04504396 NCT04504370	PMID 42964334 Frontiers in immunology, 2026 · Medium match PMID 42963740 BMC endocrine disorders, 2026 · High match PMID 42956841 Diabetes research and clinical practice, 2026 · High match

How to read this

Sites are counted from the facility lists on the registry record, with spelling variants merged. “Listed on the trial” means the registry shows the site as a location; it is not a count of patients enrolled. The method, the formula and the published tests.

Want this for your own protocol or your CRO's list?

Leave your indication and the CRO's names. We reply by email with each one checked against these records.